New Antibiotics Hailed as a 'Major Shift' in Treating Antibiotic-Resistant Gonorrhea

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to health experts.

A Global Challenge

The sexually transmitted infection are increasing globally, with data suggesting in excess of 82 million instances each year. Notably increased rates are reported in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the face of growing infection rates, escalating drug resistance and the very limited therapeutic options presently on offer.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Receive Authorization

One new antibiotic, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This approval represents a significant shift in the therapy of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Data and Global Access

According to data published in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The research included hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced positive views. Having a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is considered crucial to reduce the burden of the infection for individuals and to halt the transmission of untreatable gonorrhoea worldwide.